Back to top

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

Read MoreHide Full Article

ANI Pharmaceuticals (ANIP - Free Report) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day. This move lagged the S&P 500's daily loss of 0.75%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, lost 0.57%.

Coming into today, shares of the drugmaker had gained 2.07% in the past month. In that same time, the Medical sector lost 4.67%, while the S&P 500 gained 4%.

Investors will be hoping for strength from ANIP as it approaches its next earnings release. On that day, ANIP is projected to report earnings of $1.03 per share, which would represent a year-over-year decline of 21.97%.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.97 per share and revenue of $248 million. These totals would mark changes of +17.75% and +23.03%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for ANIP. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ANIP currently has a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that ANIP has a Forward P/E ratio of 11.9 right now. This represents a discount compared to its industry's average Forward P/E of 22.24.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 31% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow ANIP in the coming trading sessions, be sure to utilize Zacks.com.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ANI Pharmaceuticals, Inc. (ANIP) - free report >>

Published in